Case Reports
Vol. 3 No. 1 (2024)
Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 14 December 2023
Accepted: 18 March 2024
Accepted: 18 March 2024
541
Views
166
Downloads
Authors
Although the use of prophylaxis regimens with prolonged half-life factors is now widespread in the world of hemophilia A, there is a lack of real-life evidence on the impact of these products on joint health, adherence, and quality of life of patients. Turoctocog alfa pegol is a glycoPEGylated recombinant factor VIII (FVIII) with an extended half-life (EHL), developed for prophylaxis, treatment of bleeds, and perioperative management in patients with hemophilia A. We report here on three cases of three patients affected by severe hemophilia A, with variable bleeding phenotype and lifestyle, to describe our clinical practice on prophylaxis with turoctocog alfa pegol. As confirmed in our cases, FVIII trough levels remained coherent with those experienced in the registration trial after the switch to the commercial EHL drug. Moreover, the cases highlight how the current clinical management of hemophilia can personalize treatment in several specific conditions.
Downloads
Download data is not yet available.
Citations
Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost 2017;117:252-61. DOI: https://doi.org/10.1160/TH16-06-0444
Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013;11:670-8. DOI: https://doi.org/10.1111/jth.12161
Tosetto A, Neff A, Lentz SR, et al. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. Haemophilia 2020;26:450-8. DOI: https://doi.org/10.1111/hae.13980
U.S. Food and Drug Administration. Esperoct prescribing information. Available from: https://www.fda.gov/media/120351/download (accessed on October 13th, 2021)
European Medicines Agency. Esperoct. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct (accessed on October 13th, 2021)
Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost 2017;117:1705-13. DOI: https://doi.org/10.1160/TH17-03-0166
Giangrande P, Abdul Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost 2020;18:5-14. DOI: https://doi.org/10.1111/jth.14959
Iorio A, Keepanasseril A, Foster G, et al. Development of a web-accessible population pharmacokinetic service-hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc 2016;e239. DOI: https://doi.org/10.2196/resprot.6558
How to Cite
1.
Nichele I, Carli G, Tosetto A. Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life. Bleeding Thromb Vascul Biol [Internet]. 2024 Apr. 22 [cited 2025 Oct. 24];3(1). Available from: https://www.btvb.org/btvb/article/view/104
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- PO90 | Acquired hemophilia A with high-titer inhibitor in a patient with cardiovascular and metabolic comorbidities , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO65 | Utilization of emicizumab in acquired hemophilia A: a case report , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Massimo Franchini, Daniele Focosi, The changing landscape of treatment for acquired hemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CS06 | Patient specific iPSCs-derived sinusoidal endothelial cells for phenotypic correction of haemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO78 | Acquired hemophilia A as a paraneoplastic syndrome: two cases report on a rare coexistence , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO19 | Hypercoagulability in wild-type transthyretin amyloidosis: evidence from whole blood thromboelastometry , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
